Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 7/20 | 0.37 |
| ▸ | CDC25B | P30305 | 7/20 | 0.37 |
| ▸ | CDC25C | P30307 | 6/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650497 | 0.93 | CDC25A (0.45) | CDC25ACDC25BCDC25CALOX5ALDH1A1 | |
| SCHEMBL4651498 | 0.93 | CDC25A (0.45) | CDC25ACDC25BCDC25CALOX5ALDH1A1 | |
| SCHEMBL4651137 | 0.89 | — | — | |
| SCHEMBL14065968 | 0.78 | CDC25A (0.37) | CDC25ACDC25BCDC25CALOX5ALDH1A1 | |
| SCHEMBL4651092 | 0.75 | CDC25A (0.38) | CDC25ACDC25BCDC25CALOX5 | |
| SCHEMBL4651386 | 0.75 | CDC25A (0.35) | CDC25ACDC25BCDC25CALOX5 | |
| SCHEMBL4651384 | 0.75 | CDC25A (0.35) | CDC25ACDC25BCDC25CALOX5 | |
| SCHEMBL4302635 | 0.71 | CDC25A (0.60) | CDC25ACDC25BCDC25CALOX5ALDH1A1 | |
| SCHEMBL4652230 | 0.69 | CDC25A (0.43) | CDC25ACDC25BCDC25CALOX5ALDH1A1 | |
| SCHEMBL4652232 | 0.69 | CDC25A (0.43) | CDC25ACDC25BCDC25CALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294705-B1 | SYNTHESIS OF CYCLIC COMPOUNDS | BIOSIGNAL LTD (AU) | 2008-09-10 | — | — | EP | disclosed |
| US-6958145-B2 | Synthesis of cyclic compounds | UNISEARCH LIMITED (AU) | 2005-10-25 | — | — | US | disclosed |
| EP-1294705-A4 | SYNTHESIS OF CYCLIC COMPOUNDS | UNISEARCH LTD (AU) | 2005-02-09 | — | — | EP | disclosed |
| US-20040110966-A1 | Synthesis of cyclic compounds | UNISEARCH LIMITED (AU) | 2004-06-10 | — | — | US | disclosed |
| EP-1294705-A1 | SYNTHESIS OF CYCLIC COMPOUNDS | UNISEARCH LIMITED (AU) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000639-A1 | SYNTHESIS OF CYCLIC COMPOUNDS | UNISEARCH LIMITED (AU) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110966-A1 | Synthesis of cyclic compounds | RFC2, POLR2H, REV1 | CDC25A 1066/4885CDC25B 670/4885CDC25C 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.